Pulse Biosciences announced business updates and preliminary financial results for the second quarter ended June 30, 2024. Key milestones included completing the first soft tissue ablation procedures in the U.S., the first epicardial ablations in Europe, and expanding enrollment of the endocardial ablation study. Total GAAP costs and expenses were $11.7 million, while non-GAAP costs and expenses were $9.4 million. Cash and cash equivalents totaled $26.2 million as of June 30, 2024, not including $60 million in proceeds from a rights offering that closed in July 2024.